-
公开(公告)号：US20220326217A1
公开(公告)日：2022-10-13
申请号：US17640548
申请日：2020-09-04
Inventor： Eric E. Wambre , Justine J. Calise
Abstract: Provided are methods and compositions for labeling an allergen-specific pathogenic CD4+ T-cell. The method can comprise contacting a cell population comprising CD4+ T cells with a suspected allergen to provide a challenged cell population, contacting the challenged cell population, or a subpopulation thereof, with a first molecule that specifically binds to a biomarker for an allergen-specific pathogenic T cell, wherein binding of the first molecule to the biomarker on a CD4+ cell indicates the cell is an allergen-specific pathogenic CD4+ T cell, and detecting binding of the first molecule to a CD4+ cell, wherein binding to the cell indicates the cell is an allergen-specific pathogenic CD4+ T cell. The method is applicable to monitoring the presence of allergen-specific pathogenic CD4+ T cells and/or efficacy of immunotherapy for allergies in a subject.
-
公开(公告)号：US20250164481A1
公开(公告)日：2025-05-22
申请号：US19030235
申请日：2025-01-17
Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY , BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
Inventor： Joshua LaBaer , Ji Qiu , Kailash Karthikeyan , Jane Buckner , Gerald Nepom
IPC: G01N33/564 , G01N33/68
Abstract: Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody/antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.
-
公开(公告)号：US20160184262A1
公开(公告)日：2016-06-30
申请号：US14911533
申请日：2014-08-12
Applicant: BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON , THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor： Paul L. Bollyky , Nadine Nagy , Thomas Wight , Hedwich F. Kuipers
IPC: A61K31/37 , A61K31/7048
CPC classification number: A61K31/37 , A61K31/7048
Abstract: Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described.
Abstract translation: 描述了用于治疗自身免疫性，过敏性或特应性疾病的组合物，其包含抑制透明质酸合成的化合物和药学上可接受的载体。 在一些实施方案中，抑制透明质酸合成的化合物是4-甲基伞形酮或4-甲基伞形酮的代谢物。 还描述了治疗自身免疫性糖尿病，多发性硬化和/或自身免疫性脱髓鞘的方法，包括向受试者施用具有有效抑制哺乳动物受试者中透明质酸合成的量的化合物的组合物。
-
公开(公告)号：US20150362508A1
公开(公告)日：2015-12-17
申请号：US14764899
申请日：2014-01-30
Inventor： Jane Hoyt Buckner
IPC: G01N33/68
CPC classification number: G01N33/6869 , G01N33/564 , G01N2333/47 , G01N2333/5412 , G01N2333/7155 , G01N2800/24 , G01N2800/285 , G01N2800/52
Abstract: A method for identifying an autoimmune or demyelinating disease in a subject is described. The method includes (a) FIRST COHORT obtaining a sample comprising CD4′ T cells from a subject; (b) determining a level of IL-6 responsiveness of CD4+ T cells from the sample; (c) comparing the level of IL-6 responsiveness determined in step (b) with a level of IL-6 responsiveness of CD4+ T cells in a sample from a healthy subject; and (d) identifying the subject as having an autoimmune or demyelinating disease based upon an elevated level of IL-6 responsiveness in the subject. Biomarkers include, for example, IL-6Rα and/or pSTAT3. Methods for identifying and characterizing multiple sclerosis and relapsing-remitting multiple sclerosis are also described.
Abstract translation: 描述了用于鉴定个体中自身免疫或脱髓鞘疾病的方法。 该方法包括：（a）首先获得包含受试者的CD4 + T细胞的样品; （b）测定样品中CD4 + T细胞的IL-6应答水平; （c）比较步骤（b）中确定的IL-6应答水平与来自健康受试者的样品中CD4 + T细胞的IL-6应答水平; 和（d）基于受试者的IL-6反应性水平升高，将受试者鉴定为具有自身免疫性或脱髓鞘性疾病。 生物标志物包括例如IL-6Rα和/或pSTAT3。 还描述了用于鉴定和表征多发性硬化和复发性多发性硬化症的方法。
-
公开(公告)号：US12235268B2
公开(公告)日：2025-02-25
申请号：US16097791
申请日：2017-06-14
Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY , BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
Inventor： Joshua LaBaer , Ji Qiu , Kailash Karthikeyan , Jane Buckner , Gerald Nepom
IPC: G01N33/53 , G01N33/564 , G01N33/68
Abstract: Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody/antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FENI), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.
-
Patent Agency Ranking
公开(公告)号：US20240409633A1
公开(公告)日：2024-12-12
申请号：US18666000
申请日：2024-05-16
Inventor： Francisco LEON , Kevan C. HEROLD , Sarah Alice LONG , Peter S. Linsley
Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T-cells, which is indicative of successful prevention or delay of the onset of clinical T1D.
-
公开(公告)号：US20240294586A1
公开(公告)日：2024-09-05
申请号：US18251368
申请日：2021-11-03
Inventor： Jane Buckner , Eddie Arthur James , Jing Song
IPC: C07K14/47 , A61K39/00 , G01N33/564
CPC classification number: C07K14/47 , A61K39/0008 , A61K39/4611 , A61K39/4622 , A61K39/4634 , A61K39/46433 , G01N33/564 , A61K2039/5158 , G01N2440/18 , G01N2800/102
Abstract: Compositions and methods are disclosed that relate to the discovery of citrullinated oligopeptides of 9-14 amino acids or 9-18 amino acids, comprising peptide sequences derived from the polypeptide sequence of human tenascin-C (TNC) containing citrullination-dependent immunological epitopes that, remarkably, are antigen-specifically recognized by both autoantibodies and CD4+ T cells from human subjects having rheumatoid arthritis (RA). The citrullinated TNC (citTNC) oligopeptides are useful for isolating autoantibodies from, and detecting autoantibodies in, biological fluids from subjects having or suspected of having RA. Also described are uses of citTNC oligopeptides to prepare compositions for induction of citTNC autoantigen-specific immunological tolerance, including tolerogens and citTNC-specific Treg cells.
-
公开(公告)号：US10285976B2
公开(公告)日：2019-05-14
申请号：US14911533
申请日：2014-08-12
Applicant: Benaroya Research Institute at Virginia Mason , The Board of Trustees of the Leland Stanford Junior University
Inventor： Paul L. Bollyky , Nadine Nagy , Thomas Wight , Hedwich F. Kuipers
IPC: A61K31/37 , A61K31/7048
Abstract: Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described.
-
公开(公告)号：US20250154287A1
公开(公告)日：2025-05-15
申请号：US18942166
申请日：2024-11-08
Applicant: Pfizer Inc. , Benaroya Research Institute at Virginia Mason
Inventor： Edward Michael FRANKLIN , Brian Joseph FENNELL , Edwina Catherine STACK , Lidia MOSYAK , James Reasoner APGAR , Jeffrey Raymond CHABOT , Bernard KHOR , Thomas Jay MIKITA , Javier Fernando CHAPARRO-RIGGERS
Abstract: Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-α, including for example without limitation, bispecific MIGIS-α/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-α and CD3.
-
公开(公告)号：US20230279351A1
公开(公告)日：2023-09-07
申请号：US17596493
申请日：2020-06-24
Applicant: Seattle Children's Hospital (dba Seattle Children's Research Institute) , Benaroya Research Institute at Virginia Mason
Inventor： Jane Buckner , David J. Rawlings , Karen Sommer , Yuchi Chiang Honaker , Peter Cook , Akhilesh Kumar Singh , Soo Jung Yang
IPC: C12N5/0783 , C07K14/47 , C07K14/725
CPC classification number: C12N5/0637 , C07K14/4702 , C07K14/7051 , C12N2310/20 , C12N2510/00
Abstract: Some embodiments of the compositions and methods disclosed herein include gene-edited, artificial immunoregulatory T cells (airT cells) comprising a constitutively expressed FoxP3 gene product expressed at a level equal to or greater than the level of FoxP3 expression in natural T regulatory (Treg or suppressor T) cells, and a transduced (e.g., artificially engineered by gene editing, viral vector transduction, transfection or other genetic engineering methodologies) T cell receptor (TCR). In some embodiments, the TCR is preferably specific for an antigen associated with an autoimmune, allergic, or other inflammatory condition. Some embodiments include methods for the preparation and/or use of airT cells. Some such embodiments include use of airT cells for the treatment and/or amelioration of a disorder, in which antigen-specific immunosuppression may be beneficial, such as an autoimmune, allergic, or other inflammatory disorder.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
